Dako, an Agilent Technologies Company, and Cell Signaling Technology announce partnership within companion diagnostics
January 12 2015 - 9:03AM
Dako, an Agilent Technologies company
and a worldwide provider
of cancer diagnostics , and Cell Signaling
Technology (CST), a worldwide provider of antibodies, today
announced that they have entered into a strategic partnership to
supply antibodies for use in Dako-branded companion diagnostics
products.
"We are pleased to work with CST in the development of
high-quality, cutting-edge companion diagnostic products that will
be an important tool in the diagnosis and treatment of cancer,"
said Jacob Thaysen, president of Agilent's Diagnostics and Genomics
Group.
The market for companion diagnostics is steadily growing, as
personalized medicine may improve patient care and assist in
managing healthcare costs by targeting treatments to individuals
more likely to benefit from specific therapies, particularly in the
treatment of cancer.
Today's announcement follows several other collaborative
agreements in the companion diagnostics area. Agilent's Dako
business has a record of successful long-term partnerships with
companies such as Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck
& Co., Amgen and Eli Lilly, and it continues to attract new
partners.
"CST recognizes that companion diagnostic products have great
potential to improve the way we diagnose and treat patients with
cancer," said Michael J. Comb, CEO of CST. "We believe this
partnership will allow our products to contribute to the
advancement of personalized medicine."
The financial details of the agreement were not disclosed.
About Cell Signaling
Technologies
Founded by research scientists in 1999, CST is a private,
family-owned company with over 400 employees worldwide. Active in
the field of applied systems biology research, particularly as it
relates to cancer, CST understands the importance of using
antibodies with high levels of specificity and lot-to-lot
consistency. We produce all of our antibodies in house, and perform
painstaking validations for multiple applications. Technical
support is provided by the same CST scientists who produce our
antibodies, helping customers design experiments, troubleshoot, and
achieve reliable results. CST is certified by BSI to be compliant
with ISO 9001:2008 for the design, development, and production of
monoclonal antibodies. Information about CST is available at
www.cellsignal.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A), a global leader in life
sciences, diagnostics and applied chemical markets, is the premier
laboratory partner for a better world. Agilent works with customers
in more than 100 countries, providing instruments, software,
services and consumables for the entire laboratory workflow.
Agilent generated revenues of $4.0 billion in fiscal 2014. The
company employs about 12,000 people worldwide. In 2012, Agilent
acquired Dako, a well-known provider of reagents, instruments,
software and expertise to make accurate diagnoses and determine the
most effective treatment for cancer patients. Information about
Agilent is available at www.agilent.com and information about Dako
products is available at www.dako.com.
Editorial Contacts Agilent Media and Press Maia
Fredtoft Søchting Phone: +45 2546 1083 Email:
maia.sochting@agilent.com
CST Media and Press Rebecca J. Reppucci, MBA Cell Signaling
Technology, Inc. Director of Marketing Communications Phone: +1
978-867-2382 Email: marketingpr@cellsignal.com
Cell Signaling Technology®, and CST(TM) are trademarks of Cell
Signaling Technology, Inc.
HUG#1886093
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024